EPRX Latest Headlines

Eupraxia Posts Strong Long-Term Symptom Gains in Phase 1b/2a EoE Trial for EP-104GI

at www.tipranks.com (Thu, 13-Aug 8:27 AM)

Eupraxia Therapeutics: Buy Rating Reaffirmed on Advancing EoE Program and RESOLVE Phase 2b Readout, Price Target Maintained at $16

at www.tipranks.com (Wed, 12-Aug 2:55 PM)

Buy Rating Reiterated on Eupraxia Ahead of Key EP-104GI Trial Data; $11 Price Target Maintained

at www.tipranks.com (Wed, 12-Aug 1:15 PM)

Cantor Fitzgerald Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

at www.tipranks.com (Wed, 12-Aug 11:05 AM)

Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Stifel Nicolaus

at www.tipranks.com (Wed, 12-Aug 7:27 AM)

Analyst Maintains Buy on Eupraxia as Lead Asset EP-104GI Shows Strong Efficacy, Safety and Expanding Esophageal Opportunities

at www.tipranks.com (Wed, 12-Aug 4:55 AM)

Eupraxia Deepens Investment in EP-104GI as New Data Strengthen EoE Prospects

at www.tipranks.com (Tue, 11-Aug 5:35 PM)

Eupraxia Pharmaceuticals reports Q2 results

at seekingalpha.com (Tue, 11-Aug 5:29 PM)